BioSpace News Archive

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product candidates, today announced that Lindsay Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a company overview and host one-on-one investor meetings at the Raymond James Human Health Innov

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, today announced the first patient has been enrolled in the U.S. clinical study using the LungFit™ system to treat COVID-19 with NO

- Phase 1b: 7 (33%) of evaluable patients achieved an objective response, with a complete response (CR/CRi) in 5 (31%) patients treated at the four highest onvansertib dose levels - 3 (60%) of the 5 patients remain on treatment with durable response demonstrated: 6, 12 and 15 months, respectively, following the initial response; 1 patient went on to transplant - Phase 2: Of the 7 patients having completed 1 cycle of treatment, 2 (28%) achieved an objective response; 1 had

Emmes today announced that it provided the Phase 3 clinical trial support for a new investigational cell therapy that offers a promising treatment opportunity for patients who need an allogeneic bone marrow transplant. Emmes’

Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) (TSXv:GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 15/772,155, titled, “Thylakoid Extract Composition and Form

Continued Basic Science Experiments Support New Patent Filing Covering Suppression of Indolamine 2,3 Deoxygenase Pathway by QuadraMune™

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19). The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19. In addition, the exclusive license includes the use of Tempol for reducing radiation

After a nearly 40-year career with Bayer, Philip Blake, Senior Bayer Representative (SBR) and President of Bayer in the United States, has announced his retirement from this leadership role, effective July 31. Since 2012, Blake has been responsible for all U.S. activities of the worldwide Bayer Group.

Study by CHOP researchers has implications for those seeking to understand the drivers of asthma exacerbations

International Isotopes Inc. (OTCQB: INIS) (the “Company”) is pleased to announce it has hired Dr. James R. Miles, PharmD., ANP as its new Radiopharmaceutical Production Manager.